Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis

CNS Drugs
Diane Moujalled, Anthony R White

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset, neurodegenerative disease characterized by the degeneration of upper and lower motor neurons. Over recent years, numerous genes ha ve been identified that promote disease pathology, including SOD1, TARDBP, and the expanded hexanucleotide repeat (GGGGCC) within C9ORF72. However, despite these major advances in identifying genes contributing to ALS pathogenesis, there remains only one currently approved therapeutic: the glutamate antagonist, riluzole. Seminal breakthroughs in the pathomechanisms and genetic factors associated with ALS have heavily relied on the use of rodent models that recapitulate the ALS phenotype; however, while many therapeutics have proved to be significant in animal models by prolonging life and rescuing motor deficits, they have failed in human clinical trials. This may be due to fundamental differences between rodent models and human disease, the fact that animal models are based on overexpression of mutated genes, and confounding issues such as difficulties mimicking the dosing schedules and regimens implemented in mouse models to humans. Here, we review the major pathways associated with the pathology of ALS, the rodent models engineered...Continue Reading

References

Oct 1, 1995·Annals of Neurology·P J ShawD Mantle
Jul 1, 1995·Annals of Neurology·J D RothsteinR W Kuncl
Aug 16, 2000·Neuroreport·G K Dhaliwal, R P Grewal
Feb 14, 2002·Journal of Neurochemistry·Falk R WiedemannEric A Schon
Jun 13, 2002·Neuroreport·Ludo Van Den BoschWim Robberecht
Sep 25, 2002·Neurobiology of Disease·Jasna KrizJean-Pierre Julien
Jan 7, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ilias G KirkinezosCarlos T Moraes
Jul 29, 2005·Annals of Neurology·John P CrowM Flint Beal
May 23, 2006·Biochimica Et Biophysica Acta·Siân C BarberPamela J Shaw
Jun 7, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Ettore BeghiTiziana Mennini
Jun 28, 2006·Annals of Neurology·Merit E CudkowiczDaniel B Drachman
Aug 16, 2006·Neuro-degenerative Diseases·P Van DammeL Van Den Bosch
Sep 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Alberto FerriMaria Teresa Carrì
Jan 27, 2007·The Cochrane Database of Systematic Reviews·R W OrrellM Ross
Feb 16, 2007·Neurobiology of Disease·Michael Benatar
May 15, 2007·The Journal of Pharmacology and Experimental Therapeutics·Thierry BordetRebecca M Pruss
Sep 22, 2007·Annals of Neurology·David WuGuo-Fu Hu
Nov 6, 2007·Lancet Neurology·Paul H GordonUNKNOWN Western ALS Study Group
Feb 15, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Sean ScottJames A Heywood
Mar 1, 2008·Science·Jemeen SreedharanChristopher E Shaw
Jul 9, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Richard W OrrellMark Ross
Sep 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·David R BeersStanley H Appel
Nov 11, 2008·Proceedings of the National Academy of Sciences of the United States of America·Isaac M ChiuMichael C Carroll
Nov 18, 2008·Journal of Neuroimmunology·Rongzhen ZhangMichael S McGrath

❮ Previous
Next ❯

Citations

Jun 18, 2016·Expert Review of Neurotherapeutics·Yu-Ichi NotoMatthew C Kiernan
Jul 9, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Shila Azodi, Steven Jacobson
Jul 13, 2016·Acta Neuropathologica Communications·Vincent Picher-MartelNicolas Dupré
Jul 29, 2016·Angewandte Chemie·Anis TliliThierry Billard
Jan 13, 2017·Acta Odontologica Scandinavica·Birgitta Bergendal, Anita McAllister
Feb 21, 2018·Cell Death and Differentiation·Hongbo ChenDimitry Ofengeim
Nov 9, 2018·Molecular Neurodegeneration·Irene ZubiriAndrea Malaspina
Jun 16, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A V MaltsevV I Skvortsova
May 26, 2021·Orbit·Farzad PakdelNiloofar Pirmarzdashti
Jun 9, 2021·Cell Death and Differentiation·Diane MoujalledJeffrey R Liddell

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Related Papers

Biochimica Et Biophysica Acta
Philip McGoldrickLinda Greensmith
[Hokkaido igaku zasshi] The Hokkaido journal of medical science
F Moriwaka
© 2022 Meta ULC. All rights reserved